 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
11th February 2009
F2G
Ltd Announces Key Appointment and a Consolidation of the Management
Team
Manchester,
England, 11th February 2009 - F2G Limited, the Manchester UK based
antifungal drug discovery and development company, today announced the
appointment of Dr Tony Kennedy as Chief Scientific and Development Officer.
In this capacity, Dr Kennedy will be responsible for the progression
of F2G’s novel antifungal portfolio from discovery through development
and the consolidation of the F2G development function.
Prior to joining F2G, Dr Kennedy led a number of anti-infective global
development teams in Roche and SmithKline Beecham including the Roche-Gilead
Tamiflu flu antiviral global team which advanced the molecule from discovery
to registration in just over 3 years. Tony was then appointed as Roche
Global Head of Project Management and served as a member of Roche’s
Strategic Marketing Management Team and its Development Committee before
being recruited to lead the Development Functions at UK Biotechs Trigen
and Vantia.
Dr Kennedy commented “I am delighted to be joining F2G and working
with the
outstanding team who have discovered a completely new class of antifungal
agents with outstanding efficacy in preclinical efficacy models. These
agents have the potential to address the high unmet medical needs in
invasive fungal disease. I look forward to expediting the progression
of our leads to clinical study and patient trials.”
The F2G Management Team is consolidated by the promotion of Dr Mike
Birch, VP Operations, to the position of Chief Operating Officer. Dr
Birch has a strong background expertise in antifungal research and has
successfully discharged management roles of increasing responsibility
for the company prior to his new appointment.
Dr Lloyd Payne, F2G’s Chief Scientific Officer, is leaving the
company to pursue new career opportunities but will remain a consultant
to F2G Ltd. Commenting on the changes, Shane Kelly, Chief Executive
said “F2G is now poised to advance its lead antifungal assets into
clinical development and we are restructuring the management team to
equip ourselves for the challenges ahead. We are delighted to welcome
Tony to our world-class team. He has extensive drug development experience
and a successful track record of fast tracking projects through development.
I am confident that his expertise will accelerate the development of
our compounds.
Mike Birch, our new COO, has played a pivotal role in the development
of the company and in building its strong relationships with the antifungal
community both within Pharma and the clinic which will serve us well
in the period ahead.
I would like to thank Dr Lloyd Payne for serving the company with distinction
as CSO. The company wishes him well in his future career."
About
F2G Ltd:
F2G Ltd is dedicated to the discovery and development of new and clinically
superior drug classes to treat life-threatening systemic fungal infections
in at-risk patient populations. The antifungal market is currently estimated
at over five and a half billion dollars annually and is growing steadily
year on year. Market growth is expected to increase with the emergence
of new
clinical indications in allergies and asthma.
For more information visit www.f2g.com
Contact:
Shane Kelly
Chief Executive Officer
F2G Ltd
Tel: (+44) 0161 785 1271
Fax: (+44) 0161 785 1273
Email: shanekelly@f2g.com
Tel +44 (0)161 785 1270 Fax +44 (0)161 785 1273 Email contact@f2g.com